Average estimated years of life saved and associated costs by sex and age, discounted
| Sex; age at initiation of evolocumab treatment, yr | Years of treatment | YOLSs (95% CI) | Difference in lifetime cost (95% CI)* | Cost per YOLS, $ | |
|---|---|---|---|---|---|
| Untreated | Treated | ||||
| Male | |||||
| 45 | 18.6 | 19.1 | 0.45 (0.37–0.53) | 144 110 (115 628–172 593) | 318 335 |
| 55 | 15.6 | 16.0 | 0.42 (0.34–0.51) | 120 574 (97 031–144 117) | 284 306 |
| 65 | 12.1 | 12.5 | 0.36 (0.29–0.44) | 93 083 (76 276–109 890) | 257 348 |
| 75 | 8.6 | 8.8 | 0.27 (0.23–0.31) | 65 357 (54 354–76 359) | 243 414 |
| Female | |||||
| 45 | 20.0 | 20.3 | 0.29 (0.20–0.37) | 151 539 (120 778–182 299) | 528 009 |
| 55 | 16.9 | 17.2 | 0.29 (0.20–0.37) | 128 236 (102 937–153 535) | 448 221 |
| 65 | 13.3 | 13.6 | 0.26 (0.20–0.33) | 99 871 (82 313–117 430) | 382 796 |
| 75 | 9.7 | 9.9 | 0.17 (0.12–0.21) | 71 607 (60 198–83 016) | 422 710 |
| Overall† | 13.3 | 13.6 | 0.34 (0.27–0.41) | 101 899 (97 325–106 473) | 299 482 |